Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, and thank you for standing by. Welcome to the Q2 2025 ...

Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...

Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025 Operating profit increased ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Novo Nordisk AS (NVO) reports significant sales and profit growth, driven by obesity care expansion and strategic ...

Eli Lilly (NYSE:LLY) shares reached a new 52-week low on Thursday as concerns over late-stage trial data for the company’s ...

The majority of treatment-related adverse events were mild-to-moderate gastrointestinal events with no reported deaths. 2.

Novo Nordisk will hold its Q2 FY2025 earnings call on Wednesday, before the market opens. The company s having a terrible ...

Eli Lilly (LLY) stock dips as the company reports Phase 3 trial results for its oral obesity drug orforglipron. Read more ...